Chen et al. identified that CLPB, an ATPase regulator, was increased upon acquisition of Venetoclax (a BCL2 inhibitor) resistance in human AML by applying CRISPR-Cas9 screen (165). The gene discussed is BCL2; the disease is acute myeloid leukemia.